Background/Aims: Dexmedetomidine (Dex), a specific agonist of α2-adrenoceptor, has been reported to have extensive pharmacological effects. In this study, we focused on the protective effect of Dex on hyperoxia-induced acute lung injury and further explored its possible molecular mechanisms. Methods: The model of hyperoxia-induced acute lung injury was established by continuous inhalation of oxygen (FiO2= 0.90) for 7 d in neonatal rats in vivo. The in vitro experiments were carried out in LPS/ATP or hyperoxia-treated RAW264.7 cells. ELISA, western blot, TUNEL staining, and immunohistochemistry staining assays were performed and the commercial kits were used to assess the beneficial effect of Dex on hyperoxia-induced acute lung injury. Results: According to our results, Dex treatment attenuated hyperoxiainduced acute lung injury via decreasing the lung wet/dry(W/D) weight ratio and mitigating pathomorphologic changes. Moreover, the oxidative stress injury, inflammatory reaction, and apoptosis in lung epithelial cells were inhibited by Dex treatment. In addition, the activation of NLRP3 inflammasome was restrained by Dex both in lung tissue in vivo and RAW264.7 cells in vitro. Conclusion: These data provide evidence that Dex may ameliorate hyperoxiainduced acute lung injury, which suggests a potential clinical application of Dex in long-term supplemental oxygen therapy.
Introduction
Supplemental oxygen is widely used in the treatment of neonatal respiratory failure. However, long-term and continuous inhalation of high-concentration oxygen may cause various complications, such as bronchopulmonary dysplasia [1] and acute respiratory distress syndrome [2] . Therefore, it is important to search for an effective method for the treatment of hyperoxia-induced acute lung injury. 
ELISA
The levels of TNF-α, IL-6, IL-1β, IL-18, and MIP-2 were detected by ELISA assay using commercial ELISA kits (Uscn Life Science, China), following the manufacture's instructions. Concentrations of TNF-α, IL-6, IL-1β, IL-18, and MIP-2 were determined using standard curves of standard proteins.
Detection of MPO, SOD and caspase-1 activities, and MDA concentration
Lung tissues were homogenized with cold saline and centrifuged to obtain supernatant for the following detections. The activities of MPO, SOD and the concentration of MDA were determined by commercial kits (Nanjing Jiancheng, China). The activity of caspase-1 was assessed by a commercial kit (Beyotime, China) according to the manufacture's instructions.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) staining
TUNEL staining assay was performed to detect the damaged DNA in apoptotic cells in tissue samples. In Situ Cell Death Detection Kit (Roche, Switzerland) was adopted to determine the apoptosis rate in lung tissue sections. Under 400× magnification, the pictures were taken in 5 random fields for each section and the rate of TUNEL-positive cells was calculated.
Western blot analysis
The protein levels in lung tissues and cultured cells were detected by western blot analysis. Briefly, the lung tissues and RAW 264.7 cells from different groups were lysed by RIPA lysis buffer (Beyotime, China). The protein concentrations were determined by BCA protein estimation kit (Beyotime, China). Then equal amounts of protein samples were separated by SDS-PAGE, transferred to PVDF membranes. After blocked with 5% non-fat dry milk, the membranes were incubated with primary antibodies at 4 °C overnight. The primary antibodies used in this study were as follows: cleaved-caspase-3 (Cell Signaling Technology, USA), bcl-2 (BOSTER, China), bax (BOSTER, China), cleaved caspase-1 (Bioss, China), pro-caspase-1 (BOSTER, China), IL-1β p17 (Bioss, China), pro-IL-1β (Bioss, China), NLRP3 (BOSTER, China), ASC (Bioss, China) and β-actin (Santa Cruz, USA). Then the corresponding second antibodies conjugated with horseradish peroxidase were added. ECL detection reagent (7 Sea Biotech, China) was used to visualize the blots. The results were quantified with the Gel-Pro-Analyzer (Media Cybernetics, USA).
Immunohistochemistry
The expression of NLRP3 in lung tissues was detected by immunohistochemistry staining. The paraffin-embedded lung tissue sections (5 μm thickness) were deparaffinized with xylene, dehydrated by graded concentrations of alcohol, heated in retrieval solution in a microwave at low power for 10 min, and then incubated with goat serum for 15 min at room temperature. The slides were then incubated with NLRP3 primary antibody at 4 °C overnight. After washing with PBS for three times, biotin-labeled secondary antibody was added. Finally, the slides were visualized by DAB horseradish peroxidase color development Kit (Beyotime, China). Under 400× magnification, the pictures were taken in 5 random fields.
Cell culture and treatments RAW 264.7 cells were purchased from Shanghai Cell Institute Country Cell Bank and maintained in DMEM supplemented with 10% fetal bovine serum (Hyclone, USA), 100 μg/ml streptomycin and 100 U/ ml penicillin (Hyclone, USA), at 37°C, under a 5.0% CO2 atmosphere. RAW 264.7 cells were divided into the following five groups: (i) control, (ii) hyperoxia, (iii) hyperoxia+Dex, (iv) LPS+ATP, (v) LPS+ATP+Dex. The cells in hyperoxia groups were maintained in hyperoxic environment (FiO2=0.9) for 1 h. In hyperoxia+Dex group, the cells were pretreated with 1 nM Dex before the exposure to hyperoxia. For groups (iv) and (v), 100 ng/ml LPS was added to cells for 1h, then the cells in Dex treatment group were incubated with 1 nM Dex for 1h. Then 5 mM ATP was added for 1 h. The cells in control group were cultured in normoxia condition and added with equal volume solvent.
Measurement of mitochondrial membrane potential (ΔΨm)
The ΔΨm of the RAW 264.7 cells was determined by mitochondrial membrane potential assay kit with JC-1 (Beyotime, China). Briefly, RAW 264.7 cells with different treatments were incubated with 10 µg/ ml JC-1 for 20 min at 37 °C, then washed with washing buffer for two times. Fluorescence intensity was detected using fluorescent microplate reader (BioTek, USA). 
Measurement of tissue and cell mitochondrial ROS production
The mitochondria was isolated from tissue and cells by mitochondria isolation kit (Wanleibio, China), following the manufacture's instructions. Then the ROS production in mitochondria was detected by ROSspecific fluorescent probe DCFH-DA. The samples were incubated with 1mM DCFH-DA at 37℃ for 30 min. Fluorescence intensity was measured at 500 nm (excitation) and 525 nm (emission) using fluorescent microplate reader (BioTek, USA).
Statistical analysis
All experimental data are expressed as means ± standard deviation (SD). One-way analysis of variance (ANOVA) followed by a Bonferroni's Multiple Comparison Test was used to analyze the significance of differences among groups. All analyses were performed using GraphPad Prism 5 software. A p-value of less than 0.05 was considered to be a statistically significant difference.
Results

Dex alleviates hyperoxia-induced acute lung injury in neonatal rats
To determine the effect of Dex on hyperoxia-induced lung injury, the pathomorphologic changes of lung tissue were assessed by H&E staining first. As shown in Fig. 1A , exposure to hyperoxia for seven days resulted in larger alveoli and decreased interstitial thickness compared with normoxic lungs. However, Dex treatment significantly alleviated the above pathomorphologic changes, suggesting a protective effect of Dex on hyperoxia-induced lung injury. To further evaluate the protective effect of Dex, the lung W/D ratio was detected. As shown in Fig. 1B , hyperoxia enhanced the lung W/D ratio obviously compared with room air group, while Dex treatment decreased the lung W/D ratio. The results demonstrated that Dex mitigated hyperoxia-induced lung edema (room air, 4.73 ± 0.58; hyperoxia, 6.08 ± 0.85; hyperoxia+Dex, 5.00 ± 0.60).
Dex relieves inflammatory response induced by hyperoxia in vivo
To assess the severity of inflammatory cells infiltration in the lung, the number of inflammatory cells in BALF was quantified. As shown in Fig. 2A -C, the numbers of total immune cells (421000 ±120000 vs 2050000 ±449000), neutrophils (19400 ± vs 930000 ±299000) and macrophages (3600000 ±107000 vs 1020000 ±272000) in BALF were increased significantly in hyperoxia group compared to normoxic group, which could be decreased by Dex treatment effectively (total immune cells, 1220000 ±249000; neutrophils, 350000±115000; macrophages, 694000± 155000). The levels of inflammatory cytokines were determined in lung tissues and BALF ( Fig. 2D-G 
Dex suppresses oxidative stress injury induced by hyperoxia in vivo
The excess production of ROS is the main cause of oxidative stress, so the level of mitochondrial ROS in the lung tissues was assessed. As shown in Fig. 3A , there was an obvious increase in the level of ROS in hyperoxia group as compared with normoxic group, while Dex treatment dramatically decreased ROS level induced by hyperoxia (Room air, 12726±2695.600; hyperoxia, 35830.250±6692.168; hyperoxia+Dex, 24061.750±3685.382). MDA is the product of lipid peroxidation and its level was detected and showed in Fig. 3B . Hyperoxia resulted in a significant increased level of MDA in the lung tissue, which was downregulated in Dex treatment group (Room air, 24.502±6.309; hyperoxia, 53.848±14.859; hyperoxia+Dex, 34.609±7.800). SOD can scavenge oxygen free radicals and its level reflects The results are representative of three independent experiments. The values presented are mean ± SD (n = 6). **P < 0.01, ***P < 0.001, versus the room air group. # P < 0.05,
hyperoxia, 22.28%±5.47; hyperoxia+Dex, 14.81±3.44). Moreover, the levels of apoptosis related proteins in the lung tissues were determined by western blot analysis. As shown in Fig. 4C -F, the levels of cleaved caspase-3 and bax were upregulated, while the level of bcl-2 was downregulated in hyperoxia group as compared with normoxic group. However, Dex treatment could restrain hyperoxia-induced the changes in the expressions of apoptosis related proteins.
Dex suppresses hyperoxia-induced NLRP3 inflammasome activation in vivo
To assess the effect of Dex on hyperoxia-induced NLRP3 inflammasome activation, the expression of NLRP3 in lung tissues was determined by immunohistochemistry staining. As shown in Fig. 5A , treatment with Dex suppressed hyperoxia-induced upregulation of NLRP3 level in lung tissue. NLRP3 inflammasome has been proved to regulate the maturation of IL-1β, so the level of IL-1β in BALF was assessed by ELISA assay. As shown in Fig. 5B , Dex treatment significantly restrained the increased level of IL-1β induced by hyperoxia (Room Caspase-1 is activated by NLRP3 inflammasome, which may induce the maturation of IL-1β, so the activity of caspase-1 in lung tissues was determined. As shown in Fig .5C , the activity of caspase-1 was increased remarkably in hyperoxia group, which could be diminished by treatment with Dex (Room air, 2559.028±601.143; hyperoxia, 11730.900±3291.293; hyperoxia+Dex, 6406.250±1505.899). In addition, the protein levels of IL-1β, caspase-1 p10, NLRP3, and ASC in the lung tissues were upregulated by hyperoxia significantly. However, Dex treatment could downregulate the levels of those proteins ( Fig. 5D-H) .
Dex inhibits NLRP3 inflammasome activation in RAW 264.7 cells induced by hyperoxia or LPS/ATP in vitro
To further evaluate the effect of Dex on NLRP3 inflammasome activation, the RAW 264.7 cells were treated with hyperoxia or LPS/ATP. Co-incubation with LPS and ATP is reported to activate NLRP3 inflammasome. In the present study, we found that the levels of TNF-α, IL-1β, and IL-18 were increased significantly in hyperoxia or LPS/ATP group, while treatment with Dex inhibited the levels of TNF-α, IL-1β, and IL-18 effectively (Fig. 6A-C . Moreover, consistent with ELISA results, western blot assay showed that Dex inhibited hyperoxia or LPS/ATP-induced the increased protein levels of caspase-1 p10, IL-1β and NLRP3. However, Dex had no effect on hyperoxia or LPS/ATP-induced the increased levels of pro-caspase-1 and pro-IL-1β (Fig. 6D-K) .
Dex restrains ΔΨm change and mitochondrial ROS production in vitro
Mitochondrial dysfunction may trigger the release of large amounts of ROS, which leads on to the activation of NLRP3 inflammasome. Our result demonstrated that Dex alleviated the decrease in ΔΨm induced by hyperoxia or LPS/ATP (Fig. 7A) (control, 1.300±0 .157, hyperoxia, 0.301±0.044, hyperoxia+Dex, 0.803±0.026, control, 1.904±0.168, LPS/ATP, 0.648±0.062, LPS/ATP+Dex, 1.523±0.113). In addition, the increased mitochondrial ROS generation induced by hyperoxia or LPS/ATP was restrained by Dex treatment significantly (Fig. 7B) 
Discussion
Our study provides some new information about the role of Dex in hyperoxia-induced acute lung injury in vivo and in vitro. Although in our previous study, Dex was found to restrain lung injury induced by hyperoxia, the underlying molecular mechanisms are not entirely clear. In the present study, we further demonstrated that treatment with Dex restrained hyperoxia-induced inflammation response, oxidative stress damage, apoptosis in lung epithelial cells, and NLRP3 inflammasome activation, which provided additional evidence that Dex might act as a protective drug for hyperoxia-induced acute lung injury.
The typical pathological manifestations of acute lung injury are lung edema, inflammatory cells infiltration, and lung and alveolar hemorrhage [16, 17] . Several in vivo and in vitro The results are representative of three independent experiments. The values presented are mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, versus the control group. Zhang researches have showed that Dex has protective effect against lung injury induced by various pathological factors [18] [19] [20] [21] . According to our results, Dex treatment significantly reduced the number of inflammatory cells in BALF, W/D weight ratio and ameliorated the pathologic changes in the lung as compared with hyperoxia group. Pro-inflammatory cytokines play important roles in hyperoxia-induced inflammatory edema and also in turn exacerbate oxidative stress injury in lung tissue [22, 23] . MIP-2 is one of CXC chemokines, which plays pivotal roles in recruiting inflammatory cells into the lungs during acute lung injury [24, 25] . Our results revealed that exposure to hyperoxia resulted in the increased number of inflammatory cells in BALF, elevated levels of IL-1β, IL-6, TNF-α, IL-18 and MIP-2, which could be restrained by Dex treatment significantly.
The lung of neonate especially premature baby is not yet mature, so continuous inhalation of high concentrated oxygen over a long period of time may result in excessive ROS generation and cause oxidative stress injury in the lung tissue [26] [27] [28] . Parinandi et al. also demonstrated that the production of ROS was increased in hyperoxia-induced human lung endothelial cells [29] . MDA is an important product of ROS-mediated lipid peroxidation, so MDA is a surrogate marker of oxidative stress. SOD is the most efficient enzyme that can eliminate oxygen radicals, which extensively exists in the lung tissue and may act as a protection against the acute lung injury. In this study, the results indicated that the levels of ROS and MDA increased evidently, while the activity of SOD decreased in hyperoxia-induced lung tissues. As expected, Dex treatment obviously decreased the levels of ROS and MDA, increased the SOD activity in lung tissues.
Recent studies have shown that apoptosis in lung epithelial cells is an important pathological feature of hyperoxia-induced lung injury [26, 30] . O'Reilly et al. found that, compared with control group, the apoptosis rate was significantly increased in lung tissues of mice exposed to hyperoxia for 72 h [31] . Research also demonstrated that along with the time of exposure to hyperoxia extending, the number of apoptosis cells in lung tissue of neonatal mouse was increased obviously [32] . The apoptosis induced by hyperoxia is positively correlated with the severity of lung injury, which may result in blood air barrier damage and interstitial edema. Our results were consistent with previous studies and showed that hyperoxia induced a significant increase in apoptosis in lung tissues, which could be restrained by Dex treatment. Moreover, the expressions of some apoptosis related proteins were also determined. The anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bax are two important members of Bcl-2 protein family, which play a pivotal role in mitochondrial apoptosis pathway and caspases activation [33] . In this study, we demonstrated that hyperoxia up-regulated the Bax and cleaved caspase-3 levels, and down-regulated the Bcl-2 level in lung tissues obviously, which could be reversed by Dex treatment.
NLRP3 inflammasome activation participates in the progression of various inflammatory diseases. Recent researches also provided evidence that the activation of NLRP3 inflammasome was involved in ischemia-reperfusion injury [34] , atherosclerosis [35] , and hyperoxia-induced lung injury [36] . In our present study, the activation of NLRP3 inflammasome, as expected, was observed in the lung tissue of hyperoxia-treated neonatal rats. The activation of NLRP3 inflammasome subsequently activates caspase-1 that may trigger the mature of IL-1β and IL-18 by hydrolyzing pro-IL-1β and pro-IL-18. IL-1β and IL-18 are two closely related pro-inflammatory cytokines of interleukin-I family, and play pivotal roles in various immune reactions. Wang et al. demonstrated that IL-1β was initially induced in hyperoxia-induced bronchopulmonary dysplasia [37] . In the present study, the hyperoxia-induced activation of NLRP3 inflammasome was inhibited, and the increased levels of IL-1β and IL-18, enhanced activity of caspase-1 in lung tissues were also suppressed in Dex treatment group.
To further investigate the effect of Dex on hyperoxia-induced NLRP3 inflammasome activation, we performed in vitro experiments in hyperoxia or LPS/ATP-induced RAW264.7 cells. Previous studies showed that stimulation by LPS plus ATP could trigger the activation of NLRP3 inflammasome in RAW264.7 cells [38, 39] . Here, we observed that exposure to hyperoxia could result in NLRP3 inflammasome activation in RAW264.7 cells, which was Furthermore, recent research has provided evidence that mitochondrial ROS production is situated upstream of NLRP3 and has a great impact on NLRP3 inflammasome activation [40, 41] , and the decrease of ΔΨm is dependent on NLRP3 inflammasome activation induced by LPS and ATP [41] . In this study, Dex treatment inhibited the decrease of ΔΨm and mitochondrial ROS production, which restrained NLRP3 inflammasome activationmediated increased release of IL-1β, IL-18 and TNF-α. In summary, our present study demonstrates that Dex attenuates hyperoxia-induced acute lung injury. Inhibition of oxidative stress damage, inflammatory reaction, apoptosis in lung epithelial cells and NLRP3 inflammasome activation was involved in the beneficial effect of Dex. Therefore, Dex may be served as a new therapeutic approach in hyperoxiainduced acute lung injury. 
